23andMe Inc. closed its C round to raise $22 million from equity-based financing.
The Mountain View, Calif.-based genetics company said the funding came from the Johnson & Johnson Development Corp. (NYSE:JNJ), a new investor, and previous investors including New Enterprise Associates and Google Ventures (NSDQ:GOOG).
Eight un-named individuals contributed to the round, according to a Securities & Exchange Commission filing, which listed co-founder Linda Avey, co-founder and CEO Anne Wojcicki and board members Esther Dyson and NVA partner Patrick Chung.
23andMe, which takes its name from the 23 chromosomes that make up human DNA, developed a web-based, personal genetic tool called Personal Genome Service.
"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make healthcare research and healthcare delivery more efficient," Wojcicki said in prepared remarks.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.